
FDA expands Edwards’ TAVR to asymptomatic severe aortic stenosis
In a significant boost to the Edwards Lifesciences Corp. Sapien 3 platform’s market opportunity, the U.S. FDA approved use of the transcatheter aortic valve replacement in patients with asymptomatic aortic stenosis. BioWorld MedTech Regulatory …